Caplacizumab Biosimilar
REQUEST MORE INFO
Catalogue No: abx831235
Price:
US$594.50
(Size: 100 µg)
Orders to United States ship from United States
Add to Cart
Buy It Now
GET A QUOTE
Documents
Datasheet SDS
Caplacizumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting VWF A1 domain, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Caplacizumab, firstly called ALX-0081, is a humanized single-variable-domain immunoglobulin consisting of two identical humanized building blocks genetically linked by a three-alanine linker. Caplacizumab was developed by Ablynx, a Sanofi company and FDA approved on February 6, 2019, 6 and approved previously by the EU in October 2018 as a combination therapy with plasma exchange and immunosuppression.
Research Articles on VWF A1 domain
| Target | VWF A1 domain |
| Research Area | Humanized Monoclonal Antibodies, Biosimilars |
| Clonality | Monoclonal |
| Reactivity | Human |
| Expression | Recombinant |
| Tested Applications | ELISA |
| Host | Human |
| Recommended dilutions | Optimal dilutions/concentrations should be determined by the end user. |
| Conjugation | Unconjugated |
| Form | Liquid |
| Purity | > 95% |
| Purification | Purified from cell culture supernatants by Protein A/G chromatography. |
| Storage | Store at 4°C for up to 2 weeks. Aliquot and store at -20°C for long term storage. Avoid repeated freeze/thaw cycles. |
| Shelf Life | 12 months. |
| Tag | VH-VH |
| Buffer | 0.01 M PBS, pH 7.4. |
| CAS Number | 915810-67-2 |
| Concentration | Batch-dependent, typically between 0.5-2.0 mg/ml. |
| Availability | Shipped within 5-10 working days. |
| Note | THIS PRODUCT IS FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC, THERAPEUTIC OR COSMETIC PROCEDURES. NOT FOR HUMAN OR ANIMAL CONSUMPTION. |
